Resource Tracking
AVAC serves as the secretariat for the HIV
Vaccines and Microbicides
Resource Tracking Working Group, which also
includes the Alliance for
Microbicide Development, the International AIDS
Vaccine Initiative, and
UNAIDS. This year's new report along with
archives of the Working Group's
previous reports can be found at www.hivresourcetracking.org.
The HIV Vaccines and Microbicides Resource Tracking Working Group
Report 2009
Adapting to Realities: Trends in HIV Prevention Research Funding 2000 to 2008.
Released in Cape Town at the IAS conference, this year's report shows that in 2008, US$868 million was spent on vaccines, US$244 million on microbicides, and US$81 million on other new prevention options, such as pre-exposure prophylaxis using antiretroviral drugs (PrEP), and the rollout of medical male circumcision. These amounts reflect a 10 percent decline in funding for vaccines and an 8 percent increase in microbicides research funding from 2007 to 2008.
The year 2008 saw a range of funding changes from the previous year, both within and among different technologies. The overall trend for almost a decade, though, has been of increasing investment for all experimental biomedical prevention strategies. However, recent changes in scientific priorities, competing global health needs, and the downturn in the economy could impact future funding decision-making. To ensure new HIV prevention options are developed and implemented, it will be critical that HIV prevention research funding is sustained.
The HIV Vaccines and Microbicides Resource Tracking Working Group
Report 2009
Adapting to Realities: Trends in HIV Prevention Research Funding 2000 to 2008.
Released in Cape Town at the IAS conference, this year's report shows that in 2008, US$868 million was spent on vaccines, US$244 million on microbicides, and US$81 million on other new prevention options, such as pre-exposure prophylaxis using antiretroviral drugs (PrEP), and the rollout of medical male circumcision. These amounts reflect a 10 percent decline in funding for vaccines and an 8 percent increase in microbicides research funding from 2007 to 2008.
The year 2008 saw a range of funding changes from the previous year, both within and among different technologies. The overall trend for almost a decade, though, has been of increasing investment for all experimental biomedical prevention strategies. However, recent changes in scientific priorities, competing global health needs, and the downturn in the economy could impact future funding decision-making. To ensure new HIV prevention options are developed and implemented, it will be critical that HIV prevention research funding is sustained.